New Drug Protects Celiac Patients Who Eat Gluten

For the first time, researchers have shown that a medication can protect people with celiac disease from both symptoms and intestinal damage when they're exposed to gluten.

The experimental drug ANB033 kept celiac patients safe during a two-week gluten challenge, offering hope for the millions who struggle to maintain a perfectly gluten-free diet. First Tracks Biotherapeutics announced the results from their early-stage trial involving 32 patients.

All participants had lived with celiac disease for at least a year and followed a gluten-free diet. Despite their careful eating, they still had moderate gut damage when the trial began.

Patients received three injections of ANB033 over four weeks. Then came the real test: eating the equivalent of two slices of bread daily for two weeks.

The results were striking. Just 6% of patients who received ANB033 needed medication to ease their symptoms. Among those who got a placebo, nearly half needed relief.

"It is remarkable to see, for the first time, both statistically significant prevention of symptoms and intestinal benefit in the same study," said study lead Dr. Benjamin Lebwohl.

The drug works by targeting two immune system proteins, IL-15 and IL-2, that trigger the inflammation responsible for gut damage in celiac disease. By blocking these proteins, ANB033 helps prevent the body's harmful response to gluten.

The Bright Side

For people with celiac disease, even tiny amounts of gluten can cause problems. Cross-contamination in restaurants, shared kitchen equipment, and hidden ingredients make perfect avoidance nearly impossible.

ANB033 could offer protection during those unavoidable exposures. Rather than replacing the gluten-free diet, it would act as a safety net for the real-world moments when gluten sneaks in.

The trial was small, so larger studies will need to confirm these findings and check the drug's long-term safety. Researchers are already evaluating a second group of patients and expect initial results in early 2027.

Full results will be presented at the International Celiac Disease Symposium in Melbourne in November 2026. For now, the early data offers something celiac patients haven't had before: real hope for medical protection beyond diet alone.